Specifications
- Purity
- ≥98% (HPLC)
- Appearance
- Yellow to orange powder
Properties
- Solvents
- Soluble in DMF (10mg/ml). Slightly soluble in water (1mg/ml). Insoluble in ethanol.
- Melting Point
- 270 °C (lit.)
Available from stock
Cisplatin
- SKU
- C0320
Category: Antibiotics
- Synonyms
- cis-Diammineplatinum(II) dichloride, cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Neoplatin, CDDP, cis-DDP, NSC119875
- 15663-27-1
- CAS-Number
- Pt(NH3)2Cl2
- Molecular Formula
- 300.05
- Molecular Weight
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
- Shipping
- AMBIENT
- Short Term Storage
- RT
- Long Term Storage
- RT
- Handling Advice
- Protect from light and moisture.
- Use / Stability
- Stable for at least 2 years after receipt when stored at RT.
- Hazard statements
- H300 - H318 - H350
- Precautionary statements
- _x000D_P201 - P264 - P280 - P301 + P310 - P305 + P351 + P338 - P308 + P313
- GHS Symbol
- GHS05+GHS06+GHS08
- Signal word
- Danger
- RIDADR
- UN3288
- Transportation
- Packing Group II
- Description
- Cisplatin is an inorganic platinum complex with antineoplastic activity. Cisplatin is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin induces apoptosis and autophagy and activates ferroptosis. It is a potent chemoimmunotherapeutic drug and stimulates the immune responses by activating macrophages and other cells of the immune system. Cisplatin effects are regulated by kinases, phosphatases, and Ca2+/calmodulin.
- Smiles
- Cl[Pt]([NH3])(Cl)[NH3]
- InChi Key
- LXZZYRPGZAFOLE-UHFFFAOYSA-L
- References
- (1) G.R. Gale, et al.; J. Natl. Cancer Inst. 51, 1227 (1973) , (2) O. Bagasra, et al.; Cancer Immunol. Immunother. 19, 142 (1985) , (3) I. Sanchez-Perez, et al.; Oncogene 16, 533 (1998) , (4) M.S. Razzaque, et al.; Histochem. Cell Biol. 111, 359 (1999) , (5) K. Seki, et al.; Cancer Chemother. Pharmacol. 45, 199 (2000) , (6) J. Lokich; Cancer Invest. 19, 756 (2001) , (7) R.N. Bose; Mini Rev. Med. Chem. 2, 103 (2002) , (8) Z.H. Siddik; Oncogene 22, 7265 (2003) , (9) R.C. Todd & S.J. Lippard; Metallomics 1, 280 (2009) , (10) H. Han, et al.; Nature Cell Biol. 24, 74 (2022)
- InChi
- (1) H. Li et al. Bioorg. Med. Chem. 14(12), 4089 (2006) , (2) C. Liu et al.: Biochem. 35(50), 16346 (1996) , (3) J.A. Neidhart et al.: Cancer Treatment Reports 64(4-5), 553 (1980)
Cisplatin is an inorganic platinum complex with antineoplastic activity. Cisplatin is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin induces apoptosis and autophagy and activates ferroptosis. It is a potent chemoimmunotherapeutic drug and stimulates the immune responses by activating macrophages and other cells of the immune system. Cisplatin effects are regulated by kinases, phosphatases, and Ca2+/calmodulin.
Additional information
| Synonyms | cis-Diammineplatinum(II) dichloride, cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Neoplatin, CDDP, cis-DDP, NSC119875 |
|---|---|
| Purity | ≥98% (HPLC) |
| Appearance | Yellow to orange powder |
| CAS-Number | 15663-27-1 |
| Molecular Formula | Pt(NH3)2Cl2 |
| Molecular Weight | 300.05 |
| Solvents | Soluble in DMF (10mg/ml). Slightly soluble in water (1mg/ml). Insoluble in ethanol. |
| Melting Point | 270 °C (lit.) |
| Smiles | Cl[Pt]([NH3])(Cl)[NH3] |
| InChi Key | LXZZYRPGZAFOLE-UHFFFAOYSA-L |
| Shipping | AMBIENT |
| Short Term Storage | RT |
| Long Term Storage | RT |
| Handling Advice | Protect from light and moisture. |
| Use / Stability | Stable for at least 2 years after receipt when stored at RT. |
| Hazard statements | H300 – H318 – H350 |
| Precautionary statements | _x000D_P201 – P264 – P280 – P301 + P310 – P305 + P351 + P338 – P308 + P313 |
| GHS Symbol | GHS05+GHS06+GHS08 |
| Signal word | Danger |
| RIDADR | UN3288 |
| Transportation | Packing Group II |
| References | (1) G.R. Gale, et al.; J. Natl. Cancer Inst. 51, 1227 (1973), (2) O. Bagasra, et al.; Cancer Immunol. Immunother. 19, 142 (1985), (3) I. Sanchez-Perez, et al.; Oncogene 16, 533 (1998), (4) M.S. Razzaque, et al.; Histochem. Cell Biol. 111, 359 (1999), (5) K. Seki, et al.; Cancer Chemother. Pharmacol. 45, 199 (2000), (6) J. Lokich; Cancer Invest. 19, 756 (2001), (7) R.N. Bose; Mini Rev. Med. Chem. 2, 103 (2002), (8) Z.H. Siddik; Oncogene 22, 7265 (2003), (9) R.C. Todd & S.J. Lippard; Metallomics 1, 280 (2009), (10) H. Han, et al.; Nature Cell Biol. 24, 74 (2022) |
| InChi | (1) H. Li et al. Bioorg. Med. Chem. 14(12), 4089 (2006), (2) C. Liu et al.: Biochem. 35(50), 16346 (1996), (3) J.A. Neidhart et al.: Cancer Treatment Reports 64(4-5), 553 (1980) |
| Quantity | 250 mg, 1 g, Bulk |
